

Alfasigma: production plant in Sermoneta (Latina)

Today Alfasigma has four production sites in Italy: Alanno in Abruzzo, Pomezia and Sermoneta in Lazio, Trezzano Rosa In Lombardia. Sermoneta is a chemical plant, while the facilities at Alanno, Pomezia and Trezzano produce prescription and over-the-counter drugs. The Sermoneta plant (Biosint S.p.A.) produces active pharmaceutical ingredients (APIs) and nutritional ingredients for the dietary supplement market, both in Italy and abroad.

Located in the province of Latina, the Sermoneta plant employs over 100 people dedicated to production and related services.

Besides the typical operations — synthesis, concentration, crystallisation, centrifugation, drying and packaging — the facilities at this chemical plant use techniques that are not readily seen at in other similar sites, techniques such as the use of ion-exchange resins, nanofiltration and electro dialysis, even on a pilot scale.

History — The Sermoneta plant was founded in 1979 and, for over 40 years, has been a hub of chemical-pharmaceutical excellence within the area.

Dimensions — The plant consists of two adjacent production areas and covers a total area of 130,000 m², 18,000 m² of which are covered.

Production capacity — The site can produce about 260 tons per year, including the production of both active ingredients and nutritional ingredients.

Products and pharmaceutical forms – The plant manufactures active pharmaceutical ingredients and active ingredients for nutraceuticals in accordance with Good Manufacturing Practices (cGMP), with independent, fully dedicated production lines and departments.



The carnitine produced in this plant was the first to be registered as active pharmaceutical ingredient by over 30 Ministries of Health and the first to be approved by the FDA (the US body for the regulation of active ingredients and nutritional ingredients).

Biosint is ISO 9001:2015, Halal and Kosher certified. On Safety standpoint, the company is in compliance with ISO 45001:2018 rules.

News and future developments — In the next few years, we intend to further develop and diversify activities so as to position the site as a production hub for the Italian and foreign pharmaceutical and nutraceutical industry: an industrial partner of excellence for the development and manufacture of high added value products with cutting edge technological content, capable of creating business models for the development and manufacture of APIs (active pharmaceutical ingredients) and nutraceutical products.

Media Relations

CorporateCommunication@alfasigma.com

www.alfasigma.com

Last update, November 2022.